Arcus Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcus Biosciences (RCUS).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$36Upside to Avg. PT+60.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$41
Sep 30, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$43
Sep 16, 2026	TD Cowen	Tara Bancroft	Initiate	Buy	—
Sep 8, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$35→$40
Aug 6, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$23→$26
Aug 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$41→$43
Jul 20, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$32→$45
Jun 4, 2026	LifeSci Capital	Charles Zhu	Initiate	Outperform	$46
May 18, 2026	Truist Securities	Supawat Thongthip	Assumes	Buy	$30→$35
May 11, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$20→$22
May 7, 2026	Goldman Sachs	Richard Law	PT Raise	Buy	$30→$34
Apr 2, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$37→$41
Mar 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$44→$45
Mar 2, 2026	Leerink Partners	Geoffrey Porges	PT Raise	Outperform	$36→$49
Mar 2, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$32
Feb 12, 2026	Wells Fargo	Eva Fortea Verdejo	Downgrade	Overweight→Equal-Weight	$30→$23
Jan 13, 2026	Goldman Sachs	Richard Law	Upgrade	Neutral→Buy	$16→$28
Jan 8, 2026	Morgan Stanley	Terence Flynn	Downgrade	Overweight→Equal-Weight	$23→$20
Dec 12, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$28→$32
Nov 28, 2025	B of A Securities	Jason Zemansky	PT Raise	Neutral	$17→$26

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.

Benzinga Newsdesk

PRO
TD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating

TD Cowen analyst Tara Bancroft initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Buy rating.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.

Benzinga Newsdesk

Arcus Biosciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

PRO
TD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

People Also Watch

People Also Watch

Arcus Biosciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PROWedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

PROTD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating

PROTruist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PROWells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PROWedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

People Also Watch

People Also Watch

PRO
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

PRO
TD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43